Good prognosis cytogenetics in B-cell chronic lymphocytic leukemia is associated in vitro with low susceptibility to apoptosis and enhanced immunogenicity

Leukemia

Volumn 19, Issue 5, 2005, Pages 759-766

  Jahrsdorfer B ^a   Wooldridge, J E ^a   Blackwell, S E ^a   Taylor, C M ^a   Link, B K ^a   Weiner, George J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Apoptosis; Chromosomal aberration; CLL; Cytogenetics; FISH; Immunogenicity

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD38 ANTIGEN; LACTATE DEHYDROGENASE; PROTEIN BCL 2;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; BLOOD SAMPLING; CELL ADHESION; CELL STIMULATION; CELL SURVIVAL; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA CELL; LYMPHOCYTE PROLIFERATION; MALE; MIXED LYMPHOCYTE CULTURE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS;

EID: 18644363468     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403694     Document Type: Article

References (38)

1. DeVita VT, Rosenberg SA, Hellman S. Cancer, Principles and Practice of Oncology. Philadelphia: Lippincott, Williams & Wilkins, 2001, lxxii, 3235, 164pp.
2. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
3. Stilgenbauer S, Bullinger L, Lichter P, Dohner H. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 2002; 16: 993-1007.
4. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G et al. P53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580-1589.
5. Byrd JC, Smith L, Hackbarth ML, Flinn IW, Young D, Proffitt JH et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 2003; 63: 36-38.
6. Schimmer AD, Munk-Pedersen I, Minden MD, Reed JC. Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr Treat Options Oncol 2003; 4: 211-218.
7. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996; 10: 456-459.
8. Zaja F, Di Loreto C, Amoroso V, Salmaso F, Russo D, Silvestri F et al. BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine. Leuk Lymphoma 1998; 28: 567-572.
9. Morabito F, Filangeri M, Callea I, Sculli G, Callea V, Fracchiolla NS et al. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs. Haematologica 1997; 82: 16-20.
10. Johnston JB, Daeninck P, Verburg L, Lee K, Williams G, Israels LG et al. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma 1997; 26: 435-449.
11. Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, Chessia M et al. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 2002; 100: 2123-2131.
12. Goolsby CL, Kuchnio M, Finn WG, Peterson L. Expansions of clonal and oligoclonal T cells in B-cell chronic lymphocytic leukemia are primarily restricted to the CD3(+)CD8(+) T-cell population. Cytometry 2000; 42: 188-195.
13. Rezvany MR, Jeddi-Tehrani M, Rabbani H, Lewin N, Avila-Carino J, Osterborg A et al. Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia. Br J Haematol 2000; 111: 608-617.
14. Wendtner CM, Kofler DM, Theiss HD, Kurzeder C, Buhmann R, Schweighofer C et al. Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood 2002; 100: 1655-1661.
15. Chu P, Deforce D, Pedersen IM, Kim Y, Kitada S, Reed JC et al. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 3854-3859.
16. Van den Hove LE, Van Gool SW, Vandenberghe P, Bakkus M, Thielemans K, Boogaerts MA et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 1997; 11: 572-580.
17. Tretter T, Schuler M, Schneller F, Brass U, Esswein M, Aman MJ et al. Direct cellular interaction with activated CD4(+) T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro. Cell Immunol 1998; 189: 41-50.
18. Anether G, Marschitz I, Tinhofer I, Greil R. Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia. Blood 2002; 99: 722-723.
19. Jahrsdörfer B, Jox R, Muhlenhoff L, Tschoep K, Krug A, Rothenfusser S et al. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukoc Biol 2002; 72: 83-92.
20. Jahrsdörfer B, Hartmann G, Racila E, Jackson W, Mühlenhoff L, Meinhardt G et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leuk Biol 2001; 69: 81-88.
21. Decker T, Schneller F, Kronschnabl M, Dechow T, Lipford GB, Wagner H et al. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol 2000; 28: 558-568.
22. Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, Wagner H et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000; 95: 999-1006.
23. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
24. Hartmann G, Krug A, Eigler A, Moeller J, Murphy J, Albrecht R et al. Specific suppression of human tumor necrosis factor-alpha synthesis by antisense oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev 1996; 6: 291-299.
25. Hartmann G, Krug A, Bidlingmaier M, Hacker U, Eigler A, Albrecht R et al. Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes. J Pharmacol Exp Ther 1998; 285: 920-928.
26. Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods 1994; 171: 131-137.
27. Grdisa M. Influence of CD40 ligation on survival and apoptosis of B-CLL cells in vitro. Leuk Res 2003; 27: 951-956.
28. Bomstein Y, Yuklea M, Radnay J, Shapiro H, Afanasyev F, Yarkoni S et al. The antiapoptotic effects of blood constituents in patients with chronic lymphocytic leukemia. Eur J Haematol 2003; 70: 290-295.
29. Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002; 100: 2973-2979.
30. Wickremasinghe RG, Ganeshaguru K, Jones DT, Lindsay C, Spanswick VJ, Hartley JA et al. Autologous plasma activates Akt/protein kinase B and enhances basal survival and resistance to DNA damage-induced apoptosis in B-chronic lymphocytic leukaemia cells. Br J Haematol 2001; 114: 608-615.
31. Yen Chong S, Lin YC, Czarneski J, Zhang M, Coffman F, Kashanchi F et al. Cell cycle effects of IL-10 on malignant B-1 cells. Genes Immun 2001; 2: 239-247.
32. Moreno A, Villar ML, Camara C, Luque R, Cespon C, Gonzalez-Porque P et al. Interleukin-6 dimers produced by endothelial cells inhibit apoptosis of B-chronic lymphocytic leukemia cells. Blood 2001; 97: 242-249.
33. Pedersen IM, Kitada S, Leoni LM, Zapata JM, Karras JG, Tsukada N et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002; 100: 1795-1801.
34. Gamberale R, Geffner J, Arrosagaray G, Scolnik M, Salamone G, Trevani A et al. Non-malignant leukocytes delay spontaneous B-CLL cell apoptosis. Leukemia 2001; 15: 1860-1867.
35. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000; 96: 2655-2663.
36. Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410-1416.
37. Vives Corrons JL, Rozman C, Pujades MA, Colomer D, Perez Vila E, Anegon I et al. Combined assay of adenosine deaminase, purine nucleoside phosphorylase, and lactate dehydrogenase in the early clinical evaluation of B-chronic lymphocytic leukemia. Am J Hematol 1988; 27: 157-162.
38. Pepper C, Bentley P, Hoy T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br J Haematol 1996; 95: 513-517.